Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
laropiprant/niacin · 1 trial · 2 indications
Low Density Lipoprotein Cholesterol (LDL-C) after 12 weeks is calculated as the difference between week 12 measure and baseline measure divided by baseline measure \*100
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | laropiprant/niacin (MK0524A) |
| 2 | PLACEBO_COMPARATOR | placebo |
| Name | Type | Description |
|---|---|---|
| laropiprant/niacin (MK0524A) | DRUG | Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks. All patients will receive placebo for a 4 week run-in period before randomization |
| Comparator: placebo | DRUG | Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks. All patients will receive placebo for a 4 week run-in period before randomization. |
Inclusion Criteria: * Patient is male or female between 18 and 70 years of age * Females of reproductive potential must agree to take acceptable contraceptive precautions for the duration of the study Exclusion Criteria: * Patient has a history of not being able to take niacin or niacin-containin...
Laropiprant is an investigational small molecule being studied for hypercholesterolemia and rosacea. In hypercholesterolemia, it was evaluated for its effect on cholesterol levels, and in rosacea, it was studied in participants with moderate to severe erythematotelangiectatic rosacea. It is not approved and remains in clinical development.
Laropiprant is being developed by Merck & Company, Inc., which trades under the ticker MRK. The company has sponsored clinical trials of the drug for hypercholesterolemia and rosacea.
Laropiprant is in Phase 1 clinical development, based on a completed Phase 1 trial in rosacea. It has also been studied in a completed Phase 3 trial for hypercholesterolemia. The drug is investigational and not FDA approved.
Laropiprant has been studied in two completed trials. NCT00536510 was a Phase 3 trial in hypercholesterolemia and hyperlipidemia with 646 participants. NCT01451619 was a Phase 1 trial in moderate to severe erythematotelangiectatic rosacea with 60 participants.
Yes, Laropiprant is also known as MK-0524. In clinical trials, it has been referred to by this alternative name, such as in the study of Laropiprant (MK-0524) in participants with rosacea.